Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Medical Innovation Bill: Will Slow, Small And Steady Win The Race?

Executive Summary

Compared to House's 21st Century Cures package, Senate's Healthier Americans initiative is tiny, but if nothing else bills will lay important groundwork for user fee legislation.

You may also be interested in...



Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It

Bipartisan effort seems more focused on increasing cost transparency for US health care services, but stakeholders still are expected to raise drug pricing issues.

Biden’s Cancer Initiative May Intensify Industry, Government Collaboration

Drug companies and NIH embrace Vice President’s call for moonshot to cure cancer; Amgen and Celgene join separate coalition to test 60 molecules in combination Phase II studies.

Califf Supports Combo Products Pathway At Confirmation Hearing

FDA's concepts for new pathway could be ready for congressional scrutiny within a year.

Related Content

Topics

UsernamePublicRestriction

Register

PS057411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel